It looks like biotech IPOs are about to become this fall’s breakout comeback. It may be too soon to call it a full-on trend, but Evommune has just added another data point suggesting that drug developers are warming back up to the idea of going public.
Clinical Pipeline and IPO Funds
What is clear from the filing is how Evommune intends to use the money. The IPO funds would support continued progress on the company’s two drug candidates that have already reached the clinic, both currently in phase 2 testing.
One of those assets is EVO756, which Evommune plans to advance into a combined phase 2/3 program targeting chronic spontaneous urticaria (CSU) and atopic dermatitis (AD). EVO756 is an orally administered small-molecule inhibitor of MRGPRX2, a receptor predominantly expressed on mast cells and peripheral sensory neurons. The company anticipates releasing top-line results from a phase 2b study in AD sometime during the last six months of 2026.
In September, Evommune shared complete results from another phase 2 trial of EVO756 in 30 adults with chronic spontaneous urticaria (CSU). The study showed that 93% of participants experienced a clinical response by the fourth week of treatment. At the time, Mark Jackson, Evommune’s VP of clinical development, said the positive findings suggest a new treatment strategy that could address the root of the disease by calming inflammation while also quickly easing itch.
Advancing EVO301
Evommune’s other clinical candidate is EVO301, a fusion protein engineered to block IL-18 signaling. The therapy moved into a phase 2 trial for atopic dermatitis in March, with initial data expected in the first half of the coming year. In its SEC filing, the company said it believes EVO301’s refined method of targeting and blocking IL-18 could offer meaningful benefits that set it apart clinically, including potential improvements in effectiveness, tissue penetration, dosing needs and the likelihood of triggering an immune response.
The company intends to start a phase 2 study of EVO301 in ulcerative colitis next year and is also eyeing future trials in Crohn’s disease and additional inflammatory indications.
Financials and Market Trends
Evommune’s most recent fundraise was a $115 million Series C completed a year ago, backed by RA Capital Management and Sectoral Asset Management. As of June 2025, the company reported having $86.8 million in cash.
A small wave of biotech IPOs emerged early in the year but quickly faded as market uncertainty intensified. Evommune’s move now suggests that some drug developers are once again testing their luck with the public markets. A month ago, CNS specialist LB Pharmaceuticals debuted on the public markets with a $285 million IPO. Meanwhile, MapLight Therapeutics is aiming to pull in as much as $262 million through its own offering as it prepares to take on Bristol Myers Squibb’s schizophrenia drug Cobenfy.
New Insights & Patient Impact
Evommune’s drug pipeline shows promise not only because of the impressive early data but also in how the drug-treatments may alter patient experience. With EVO756’s rapid itch relief and high rates of response, patients who currently rely on biologic injections may have an oral‐drug alternative in the near future. This could lead to fewer visits, more convenience, and possibly improved adherence.
Moreover, EVO301’s approach of targeting IL-18 could open doors for treating multiple inflammatory diseases, possibly in settings where immune modulation is essential but current options are limited. For example, therapies for ulcerative colitis or Crohn’s disease that rely on biologics often come with risks or limitations—Evommune’s drug candidates may provide improved tissue targeting or longer duration of action.
There are challenges ahead. Drug development always bears risk: unexpected adverse events, regulatory hurdles, manufacturing scale, and reimbursement issues. But Evommune seems well-positioned, with sufficient financing and strong early‐stage clinical proof points.
